Home / Discussion / Supplement / Links / Posttest
Baer L, Jacobs DG, Meszler-Reizes J, et al. Development of a brief screening instrument: the HANDS. Psychother Psychosom 2000;69:35-41
Claxton A, de Klerk E, Parry M, et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 2000;61:928-932
Clinical Practice Guideline Number 5: Depression in Primary Care, vol. 2. Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551
Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(suppl 22):30-33
Depression Is a Treatable Illness: A Patient’s Guide. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0553
Dinan TG. Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. J Clin Psychiatry 2001;62(suppl 22):48-52
Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-222
Feiger AD, Bielski RJ, Bremner J, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999;14:19-28
Frank E, Judge R. Treatment recommendations versus treatment realities: recognizing the rift and understanding the consequences. J Clin Psychiatry 2001;62(suppl 22):10-15
Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 1991;48:851-855
Keller MB, Gelenberg AJ, Hirshfeld RM, et al. The treatment of chronic depression, pt 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998;59:598-607
Kocsis JH, Friedman RA, Markowitz JC, et al. Maintenance therapy for chronic depression: a controlled clinical trial of desipramine. Arch Gen Psychiatry 1996;53:769-774; discussion 775-776
Koran LM, Gelenberg AJ, Kornstein SG, et al. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 2001;65:27-36
Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
Montgomery SA, Dufour H, Brian S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;3(suppl 3):69-76
Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-195
Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-188
Schmidt ME, Bergstrom R, Fava M, et al. Response to an increased dose of fluoxetine by patients relapsing during long-term treatment of depression. In: New Research Abstracts of the Annual Meeting of the American Psychiatric Association; May 10, 2001; New Orleans, La. Abstract NR830:224-5
Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000;61:851-857
Home / Discussion / Supplement / Links / Posttest